“Gut Microbiota Metabolites As A New Therapeutic Target In Patients With Coronary Artery Disease And Atrial Fibrillation”. 2023. Journal of Pharmaceutical Negative Results, January, 1221-27. https://doi.org/10.47750/pnr.2023.14.02.157.